Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This trial is to compare the efficacy and safety of modified FOLFOX6 [mFOLFOX6, a specific
chemotherapy regimen of Oxaliplatin ,5-Fluorouracil and Leucovorin] chemotherapy plus Antigen
Pulsed Dendritic Cells (APDC，a kind of autologous tumor lysates pulsed human dendritic cells
vaccine) with modified chemotherapy alone in patients with metastatic colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Second Military Medical University
Collaborators:
307 Hospital of PLA Beijing Cancer Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences Changhai Hospital Chinese PLA General Hospital First People's Hospital of Hangzhou Fudan University Huashan Hospital RenJi Hospital Ruijin Hospital Second Affiliated Hospital, School of Medicine, Zhejiang University Shanghai Changzheng Hospital Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Haixin Biotechnology Co. Ltd The 307th Hospital of Chinese People`s Liberation Army Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Zhejiang Cancer Hospital